Detection of peptide structures for diagnosing and treating sepsis and covid
AssigneeVenn Biosciences Corporation
InventorsChad Eagle PICKERING, Gege XU, Hector Han-Li HUANG, Xin CONG
Life of this patent
Estimating the term…
Loading patent…
AssigneeVenn Biosciences Corporation
InventorsChad Eagle PICKERING, Gege XU, Hector Han-Li HUANG, Xin CONG
Estimating the term…
Embodiments disclosed herein generally relate to technologies for evaluating a biological sample obtained from a subject with respect to a sepsis state or coronavirus disease (COVID). Some methods relating to the technologies can include receiving peptide structure data corresponding to the biological sample obtained from the subject, identifying a peptide structure profile for the biological sample using the peptide structure data, and computing a disease indicator using the peptide structure profile and a model. The disease indicator can indicate whether the biological sample is positive for the sepsis state. The disease indicator can indicate whether the biological sample is positive for COVID. The peptide structure profile can comprise quantification data for a set of peptide structures associated with the sepsis state. The peptide structure profile can include peptides that are glycosylated, aglycosylated, or both. An additional step in the method can comprise generating at least one of a diagnosis output or a treatment output based on the disease indicator.
A method of determining whether a biological sample corresponds to a sepsis state, the method comprising:
A method of identifying a sepsis-specific set of peptide structures for use in diagnosing a sepsis state, the method comprising:
A method of evaluating a biological sample obtained from a subject with respect to a sepsis state, the method comprising:
A method for analyzing a set of peptide structures in a sample from a patient, the method comprising:
A composition comprising at least one of peptide structures PS-1 to PS-46 identified in Table 1.
A composition comprising a peptide structure or a product ion, wherein:
A composition comprising a glycopeptide structure selected as one from a group of glycopeptide structures consisting of:
A composition comprising a peptide structure selected as one from a group of aglycosylated peptide structures consisting of:
A method of determining whether a biological sample corresponds to a symptomatic disease state of a coronavirus disease (COVID), the method comprising:
A method of identifying a coronavirus disease (COVID)-specific set of peptide structures for use in diagnosing a symptomatic disease state of the coronavirus disease, the method comprising:
A method of diagnosing a symptomatic disease state of a coronavirus disease (COVID), the method comprising:
A method of evaluating a biological sample obtained from a subject with respect to a symptomatic disease state corresponding to a coronavirus disease (COVID), the method comprising:
A method for analyzing a set of peptide structures in a sample from a patient, the method comprising:
The method of claim 13336, wherein the sample comprises a plasma sample.
A composition comprising at least one of peptide structures PS-1 to PS-45 identified in Table 1-1.
A composition comprising a peptide structure or a product ion, wherein:
A composition comprising a glycopeptide structure selected as one from a group of glycopeptide structures consisting of:
A composition comprising a peptide structure selected as one from a group of aglycosylated peptide structures consisting of:
A method of diagnosing a coronavirus disease (COVID) in a subject, comprising the step of identifying one or more peptide structures identified in Table 2-1 from a sample from the subject.
A method of identifying a subject suitable for, or in need of, COVID prevention or treatment, the method comprising the step of measuring from a biological sample taken from the subject for the presence of one or a combination of peptide structures identified in Table 2-1, wherein their detection indicates that the subject should have COVID prevention or treatment.
A method of predicting whether a subject will be symptomatic upon coronavirus infection, comprising the step of measuring from a biological sample taken from the subject for the presence of one or a combination of peptide structures identified in Table 2-1.
Dependencies are inferred from the claim text.